BERKELEY, CA--(Marketwired - Dec 29, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) for up to $40 million of total funding. Dynavax drew the first tranche of $10 million on closing and has access to an additional $30 million in 2015, at Dynavax's option, if it achieves certain milestones relating to the ongoing Phase 3 study of HEPLISAV-BT (HBV-23).